Indian researchers have identified a specific genetic defect that triggers breast cancer hormone resistance in many patients. Dr. Amit Dutt and Dr. Sudeep Gupta led the study, which highlights why nearly 40% of patients with HR+/HER2-negative breast cancer stop responding to standard therapies. The British Journal of Cancer published this discovery, which offers a new pathway for personalized oncology in India.

Understanding Breast Cancer Hormone Resistance and CDKN1B

The team discovered that the loss of the CDKN1B gene directly causes breast cancer hormone resistance. Normally, this gene produces the p27 protein, which acts as a protective brake on tumor growth. Damage to this gene makes tumors resistant to common drugs like tamoxifen and aromatase inhibitors. Interestingly, the researchers analyzed 186 Indian patients and found this defect only in those who relapsed.

Implementing Precision Treatment Strategies

Consequently, this discovery could revolutionize how doctors manage high-risk patients. Since laboratories can measure p27 levels through routine pathology tests, early identification is now possible. Furthermore, the team confirmed their findings by restoring p27 in laboratory cells, which successfully resumed drug sensitivity. Therefore, patients lacking p27 might benefit from stronger combination therapies before a relapse occurs. This research emphasizes the value of Indian genomic data in tailoring cancer care.

Frequently Asked Questions

Q1: Why do some breast cancer patients stop responding to hormone therapy?

Research indicates that the loss of the CDKN1B gene prevents the production of the p27 protein. Without this protein, cancer cells can bypass the inhibitory effects of standard hormone drugs, leading to resistance.

Q2: How can doctors identify patients at risk of treatment failure?

Pathologists can check p27 levels using routine diagnostic tests on tumor samples. Low or absent p27 levels signal a high risk of developing resistance to standard hormone treatments.

Q3: What are the treatment options if this genetic defect is found?

Doctors may initiate stronger combination therapies earlier in the treatment plan. Identifying the defect early allows for more aggressive or targeted approaches to prevent a relapse.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Scientists identify genetic defect that makes breast cancer treatmentineffective - ETHealthworld


2. Ahmad, S., et al. (2026). CDKN1B loss-of-function drives endocrine resistance in HR+/HER2− breast cancer. British Journal of Cancer.


3. Tata Memorial Centre. (2026). Genomic characterization of treatment resistance in Indian breast cancer cohorts.